nosopharm.com
Brèves | Nosopharm
http://www.nosopharm.com/fr/news/breves
Aller au contenu principal. Nosopharm participera au Re-entering Antibacterial Drug Development Summit 2015 (16-18 novembre, Boston, USA). Nosopharm sera à Boston (USA) du 16 au 18 novembre 2015 pour participer au Re-entering Antibacterial Drug Development Summit. Et rencontrer de nombreux experts du développement industriel des antibiotiques. Lire la suite de Nosopharm participera au Re-entering Antibacterial Drug Development Summit 2015 (16-18 novembre, Boston, USA). Appelée la BEAM Alliance. Nosopharm...
technophage.pt
TechnoPhage is one of the Founding Members of BEAM ALLIANCE
http://www.technophage.pt/index.php/news2015/item/38-technophage-is-one-of-the-founding-members-of-beam-alliance
TechnoPhage, SA - From science to innovative biopharmaceuticals. TechnoPhage is one of the Founding Members of BEAM ALLIANCE. TechnoPhage is one of the Founding Members of BEAM ALLIANCE. June 30, 2015. TechnoPhage is one of the Founding Members of BEAM ALLIANCE, the newly launched alliance of Biotech’s of Europe innovating in Anti-Microbial Resistance. For more information click here. TechnoPhage is currently looking for a candidate to apply for a FCT post-doc fellowship. New patent granted to TechnoPhage.
antibiotic-action.com
Global Initiatives
http://antibiotic-action.com/aa_global_initiatives
Antibiotic Action is a public engagement initiative to raise awareness about the dangers of antibiotic-resistant bacteria. Let’s help raise awareness! Visit the page, like them and share the messages with friends, family and colleagues. Meetings & Events. Resources and Access to the Antimicrobial Resource Centre. Supporters & Partners. Meetings & Events. Antibiotic Action welcomes CARB-X and $100 million funding to tackle AMR. EMA Recommends Reduction in Colistin Use in Animals. No Antibiotics - No cure.
antabio.com
Antabio is now a member of the newly launched BEAM Alliance - Antabio
http://www.antabio.com/antabio-is-now-a-member-of-the-newly-launched-beam-alliance
Antabio is now a member of the newly launched BEAM Alliance. Antabio is now a member of the newly launched Alliance of Biotechs of Europe innovating in Anti-Microbial Resistance, called the BEAM Alliance. This group of European biotechnology companies is committed to tackling the unique challenges facing the industry in the antibacterial field and currently regroups 34 companies from 10 European countries. For more information, please visit http:/ beam-alliance.eu/. Wordpress website by PICT AO.
nosopharm.com
Toute l'actualité | Nosopharm
http://www.nosopharm.com/fr/news
Aller au contenu principal. COMMUNIQUE DE PRESSE : Nosopharm rejoint le projet European Gram-negative Antibacterial Engine (ENABLE) pour lutter contre la résistance aux antibiotiques. La société prévoit d’amener NOSO-95179, un antibactérien prometteur, jusqu’au stade clinique pour le traitement des infections provoquées par des bactéries à gram-négatif multirésistantes. Nosopharm participera au Re-entering Antibacterial Drug Development Summit 2015 (16-18 novembre, Boston, USA). Appelée la BEAM Alliance.
destinypharma.com
News | Destiny Pharma
http://www.destinypharma.com/news_current.shtml
Incentives for New Antibacterial Drugs. Destiny Pharma invited to present at the inaugural Superbugs & Superdrugs USA Conference & Exhibition on the 14th and 15th November 2016 in New Jersey, USA. July 8, 2016. Destiny Pharma has been invited to present at the inaugural Superbugs and Superdrugs USA Conference and Exhibition. If you would like to arrange a meeting during Superbugs and Superdrugs USA. Destiny Pharma Welcomes O’Neill Report on Tackling Antimicrobial Resistance (AMR). May 19, 2016. And recom...
berlin-conferences.com
Berlin Conference on Life Sciences 2017: Partners & Sponsors
http://berlin-conferences.com/partners-sponsors
The Berlin Conference on Life Sciences was supported by these institutions:.
deinove.com
DEINOBIOTICS | Deinove
http://www.deinove.com/fr/programmes-et-applications/deinobiotics
S'inscrire aux alertes e-mail. Partenaires industriels and technologiques. Partenaires scientifiques and institutionnels. DEINOVE, actionnaire fondateur de DEINOBIOTICS. Afin de valider le potentiel antibactérien de sa deinothèque, DEINOVE a lancé en 2009 un programme de recherche exploratoire avec le soutien d’OSEO, de la Région Languedoc-Roussillon et du Fonds européen de développement régional (FEDER). Aujourd’hui, le programme de R&D de DEINOBIOTICS cible prioritairement des antibiotiques à même de l...
SOCIAL ENGAGEMENT